Published in J Clin Oncol on March 15, 2010
PTC596 in Patients With Advanced Solid Tumors | NCT02404480
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma | NCT01105702
68Ga-citrate PET/MR Imaging for Glioma | NCT03335280
Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma | NCT04530006
3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging (2012) 6.36
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Childs Nerv Syst (2014) 2.66
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol (2015) 2.60
Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol (2012) 2.31
Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol (2015) 2.21
Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int (2013) 2.12
The comprehensive neuro-oncology data repository (CONDR): a research infrastructure to develop and validate imaging biomarkers. Neurosurgery (2014) 2.02
Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. Int J Radiat Oncol Biol Phys (2015) 1.99
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.95
The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS). IEEE Trans Med Imaging (2014) 1.91
The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology (2011) 1.80
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol (2011) 1.76
Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma. Clin Cancer Res (2015) 1.73
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. J Clin Invest (2014) 1.66
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol (2012) 1.65
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res (2011) 1.64
Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival. World Neurosurg (2011) 1.62
Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities. Sci Transl Med (2015) 1.59
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol (2010) 1.59
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med (2016) 1.56
Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology (2013) 1.55
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol (2013) 1.51
Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol (2015) 1.50
Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol (2011) 1.45
Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. J Magn Reson Imaging (2013) 1.43
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol (2012) 1.42
Biomarker based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models. Cancer Res (2017) 1.42
Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol (2011) 1.42
Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol (2011) 1.40
Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res (2011) 1.39
Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology (2011) 1.38
Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol (2012) 1.38
Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol (2012) 1.37
Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods. Cancer Manag Res (2014) 1.35
Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res (2012) 1.35
Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging (2012) 1.34
Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep (2011) 1.34
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol (2016) 1.32
Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat Rev Neurol (2013) 1.31
Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI. NMR Biomed (2011) 1.30
Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol (2013) 1.30
Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol (2011) 1.29
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol (2011) 1.29
Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res (2014) 1.28
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol (2015) 1.27
Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol (2015) 1.26
Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol (2014) 1.26
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging (2014) 1.26
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol (2013) 1.25
Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Dev Immunol (2011) 1.24
Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology (2014) 1.23
The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med (2012) 1.21
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol (2015) 1.20
ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology (2010) 1.20
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol (2014) 1.19
3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med (2011) 1.18
Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol (2012) 1.17
Advanced magnetic resonance imaging of the physical processes in human glioblastoma. Cancer Res (2014) 1.16
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw (2011) 1.16
Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol (2012) 1.16
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer (2011) 1.16
Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep (2013) 1.16
Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article. J Neurosurg (2010) 1.15
Building better monoclonal antibody-based therapeutics. Nat Rev Cancer (2015) 1.15
Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Eur J Nucl Med Mol Imaging (2012) 1.14
Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med (2013) 1.13
Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol (2014) 1.13
MRI perfusion in determining pseudoprogression in patients with glioblastoma. Clin Imaging (2012) 1.13
Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol (2011) 1.13
Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging (2012) 1.12
Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res (2014) 1.12
Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question. Neuro Oncol (2014) 1.12
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol (2011) 1.09
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Quantitative Imaging in Cancer Clinical Trials. Clin Cancer Res (2016) 1.08
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol (2013) 1.07
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs (2013) 1.07
Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric. PLoS One (2013) 1.07
Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol (2015) 1.06
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer (2012) 1.06
Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics (2011) 1.06
Peri-ictal pseudoprogression in patients with brain tumor. Neuro Oncol (2011) 1.06
Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. Curr Oncol (2011) 1.06
Multi-modal glioblastoma segmentation: man versus machine. PLoS One (2014) 1.05
Biopsy versus partial versus gross total resection in older patients with high-grade glioma: a systematic review and meta-analysis. Neuro Oncol (2015) 1.05
Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol (2011) 1.05
Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol (2013) 1.05
Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One (2011) 1.05
Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol (2010) 1.05
Functional imaging in adult and paediatric brain tumours. Nat Rev Clin Oncol (2012) 1.05
Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival. Neuro Oncol (2013) 1.04
Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging. Neuro Oncol (2013) 1.04
Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol (2013) 1.04
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 25.96
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med (2014) 9.19
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med (2014) 9.09
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Angiogenesis in brain tumours. Nat Rev Neurosci (2007) 6.82
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 6.54
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol (2008) 6.41
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol (2012) 5.71
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (2012) 5.09
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol (2008) 4.66
Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A (2005) 4.63
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature (2011) 4.63
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst (2005) 4.63
An integrative approach for in silico glioma research. IEEE Trans Biomed Eng (2010) 4.55
Segmentation of subcomponents within the superior longitudinal fascicle in humans: a quantitative, in vivo, DT-MRI study. Cereb Cortex (2004) 4.50
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol (2012) 4.27
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol (2005) 4.10
Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood (2010) 3.99
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med (2009) 3.85
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene (2003) 3.83
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer (2012) 3.66
A multigene predictor of outcome in glioblastoma. Neuro Oncol (2009) 3.57
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol (2007) 3.53
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol (2014) 3.52
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol (2013) 3.52
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol (2008) 3.50
Inequality in early childhood: risk and protective factors for early child development. Lancet (2011) 3.48
Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology (2015) 3.48
Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res (2004) 3.47
Tracer arrival timing-insensitive technique for estimating flow in MR perfusion-weighted imaging using singular value decomposition with a block-circulant deconvolution matrix. Magn Reson Med (2003) 3.44
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res (2006) 3.41
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res (2003) 3.36
Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res (2005) 3.35
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol (2009) 3.32
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res (2006) 3.31
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29
Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol (2004) 3.25
Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res (2009) 3.22
DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol (2011) 3.18
Gene expression profiling identifies molecular subtypes of gliomas. Oncogene (2003) 3.13
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A (2012) 3.12
An evidence-based causative classification system for acute ischemic stroke. Ann Neurol (2005) 3.09
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol (2007) 3.07
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med (2002) 3.03
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol (2009) 3.02
Targeted molecular therapy of GBM. Brain Pathol (2003) 3.02
Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol (2007) 2.93
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol (2008) 2.92
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther (2007) 2.89
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer (2008) 2.89
Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol (2008) 2.84
The cerebrospinal fluid provides a proliferative niche for neural progenitor cells. Neuron (2011) 2.83
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol (2006) 2.81
Diffusion tensor imaging as potential biomarker of white matter injury in diffuse axonal injury. AJNR Am J Neuroradiol (2004) 2.78
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (2010) 2.71
MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol (2005) 2.70
Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene (2002) 2.69
Integrated morphologic analysis for the identification and characterization of disease subtypes. J Am Med Inform Assoc (2012) 2.68
A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke (2007) 2.63
On-line automatic slice positioning for brain MR imaging. Neuroimage (2005) 2.62
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61